Cannabidiol

Travelling for March Break? The Canada Border Services Agency gives tips for a smoother trip

Retrieved on: 
Thursday, February 29, 2024
Canada Border Services Agency, Atmosphere, Health Canada, Indigenous peoples, Narcotic, Letter, Holiday, Safety, Arrest, THC, Tobacco, Cannabidiol, Oil, Child, Cannabis, Movement, CBSA, Firearm, Water, Travel

OTTAWA, ON, Feb. 29, 2024 /CNW/ - The Canada Border Services Agency (CBSA) reminds travellers of what to expect when crossing the border during March break.

Key Points: 
  • OTTAWA, ON, Feb. 29, 2024 /CNW/ - The Canada Border Services Agency (CBSA) reminds travellers of what to expect when crossing the border during March break.
  • Here are some tips to help you plan for your trip:
    Plan ahead, expect delays and check border wait times .
  • Travellers crossing the border by land are encouraged to cross during non-peak hours such as early mornings.
  • Border services officers are always watching for missing children , and in the absence of the letter, officers may ask additional questions.

Avicanna Obtains Its First Indication-Specific Drug Registration with Trunerox™

Retrieved on: 
Tuesday, February 13, 2024
Health authority, Altea, TSX, SAS, GMP, Dravet syndrome, LGS, Patient, CBD, Lennox–Gastaut syndrome, Cannabidiol, Seizure, Pharmaceutical industry

“The approval of our first pharmaceutical product is an exceptionally significant milestone and a major step towards our long-term vision as a biopharmaceutical company with the aim to serve patients with unmet medical needs.

Key Points: 
  • “The approval of our first pharmaceutical product is an exceptionally significant milestone and a major step towards our long-term vision as a biopharmaceutical company with the aim to serve patients with unmet medical needs.
  • It is also rewarding to be able to deliver this medication for such a critical medical condition at an accessible price through our vertical,” stated Aras Azadian, CEO.
  • The approval allows Avicanna to manufacture and commercialize Trunerox in Colombia with approved indications and claims associated to the treatment for seizures related to Lennox-Gastaut Syndrome (LGS) and Dravet Syndrome (DS).
  • Lennox-Gastaut Syndrome (LGS) and Dravet Syndrome (DS) are two of the various, rare epileptic disorders classified as epileptic encephalopathies.

Danish dog owners are medicating their pets with unlicensed cannabis products – is it safe?

Retrieved on: 
Tuesday, February 6, 2024
Anxiety, Attention, Cannabis, Cannabidiol, Chronic pain, Travel, THC, Migraine, Research, Edible, Toxicity, Lethargy, Safety, Food, Dog, Oil, Cannabinoid, Osteoarthritis, Skin, Saliva, Thought, Pain management, Vomiting, Cat, Allergy, Health, Diarrhea, Pet, Medical imaging

Unsurprisingly, this trend has made its way to our pets, with a recent study suggesting that 38% of surveyed Danish dog owners routinely gave their pets some form of cannabis product.

Key Points: 
  • Unsurprisingly, this trend has made its way to our pets, with a recent study suggesting that 38% of surveyed Danish dog owners routinely gave their pets some form of cannabis product.
  • Previous studies suggest that 80% of dog owners in the US and Canada had bought cannabis products for their pet.
  • But, is CBD safe for our pets and could it be a useful addition to our pet’s healthcare regime?
  • Indeed, 36% of respondents in the Danish study indicated that they used cannabinoids for pain management in their pets.

Study on the safety of Elixinol Hemp Extract is published in Journal of Toxicology

Retrieved on: 
Friday, February 2, 2024
Cannabidiol, Toxicity, Extract, Safety, Journal, Rat, Health, ASX, Dietary supplement

The paper, entitled "Safety of Elixinol Hemp Extract: In VitroGenetic Toxicity and Subchronic Toxicity in Rat", reports on safety studies of Elixinol Hemp Extract in rats and concludes that the Extract is safe to use and does not have any adverse effects at the highest dose tested.

Key Points: 
  • The paper, entitled "Safety of Elixinol Hemp Extract: In VitroGenetic Toxicity and Subchronic Toxicity in Rat", reports on safety studies of Elixinol Hemp Extract in rats and concludes that the Extract is safe to use and does not have any adverse effects at the highest dose tested.
  • The paper also suggests that the Elixinol Hemp Extract may have some benefits for human health, with additional studies needed to confirm this.
  • Elixinol Group CEO and Managing Director, Ron Dufficy, said: "The positive safety results, now published in a well-respected scientific journal, stand Elixinol Hemp Extract and Elixinol more broadly in good stead for the future of our hemp products and offerings."
  • Elixinol Hemp Extract contains a blend of hemp extract, cannabidiol (CBD) isolate, and copaiba.

SciSparc Announces Initiation of Patient Recruitment for its Clinical Trial with SCI-210 in Children with Autism Spectrum Disorder

Retrieved on: 
Monday, January 29, 2024
ASD, Spectrum, Health, Soroka Medical Center, Social, Cannabidiol, Communication, Deviance (sociology), TEL, CBD, Central nervous system, Clinical trial, Behavior, Trial of the century

TEL AVIV, Israel, Jan. 29, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, today announces the initiation of patient recruitment for its clinical trial in children suffering from autism spectrum disorder ("ASD") at Soroka Medical Center in Israel.

Key Points: 
  • The Company's goal is to sell SCI-210 first in Israel and then in other countries, subject to obtaining the requisite regulatory approvals.
  • “We hope the outcome of the trial will enable the Company to procced with the commercialization process for SCI-210 in Israel."
  • The trial was designed in consultation with the National Autism Research Center, the leading research center for autism in Israel.
  • The term "spectrum" in autism spectrum disorder refers to the wide range of symptoms and severity.

Incannex Commences Dosing in Phase 2 Clinical Trial Assessing IHL-675A in Patients with Rheumatoid Arthritis

Retrieved on: 
Wednesday, January 24, 2024
Magnetic resonance, Antigen presentation, Patient, Chronic obstructive pulmonary disease, IP, MRI, Inflammatory bowel disease, Pharmacokinetics, Rheumatoid arthritis, Asthma, Fatigue, Joint stiffness, IBD, API, HCQ, Cannabidiol, COPD, Quality of life, Plasma, NDA, FDA, Pain, Lupus erythematosus, Inflammation, Biomarker, Epilepsy, Magnetic resonance imaging, Hydroxychloroquine, Pharmaceutical industry

The primary endpoint of the double-blind, Phase 2 clinical trial is pain and function relative to baseline determined via the score on the RAPID-3 assessment at 24 weeks.

Key Points: 
  • The primary endpoint of the double-blind, Phase 2 clinical trial is pain and function relative to baseline determined via the score on the RAPID-3 assessment at 24 weeks.
  • Chief Scientific Officer of Incannex, Dr. Mark Bleackley, said; “Commencing dosing in the Phase 2 clinical trial in patients with RA is an exciting milestone for the development of IHL-675A.
  • Millions of people are affected by pain associated with rheumatoid arthritis despite the available treatment options.
  • Overview of Results from Phase 1 Clinical Trial Assessing Tolerability, Safety, and Pharmacokinetics of IHL-675A in Healthy Volunteers
    In 2022 and 2023, Incannex undertook a Phase 1 clinical trial to assess the safety, tolerability, and pharmacokinetics of IHL-675A.

Sipp Industries Announces Distribution Agreement for Patented SinuSave® CBD Nasal Spray

Retrieved on: 
Tuesday, January 23, 2024
Sinusitis, Originality, Partnership, Common, Cannabidiol, OTC, CBD, Pain, Allergy, Marketing, Air pollution, Pharmaceutical industry

SinuSave® CBD Nasal Spray, offering a range of patented CBD nasal spray products in 500mg and 1000mg strengths, is poised to transform the wellness industry.

Key Points: 
  • SinuSave® CBD Nasal Spray, offering a range of patented CBD nasal spray products in 500mg and 1000mg strengths, is poised to transform the wellness industry.
  • SinuSave® CBD is the only all-natural drug-free patented product specifically designed for daily nasal hygiene of its type.
  • "This partnership with SinuSave® represents an exciting leap forward for SIPP Industries," said Jakob Jorgensen, CEO of SIPP Industries.
  • "The SinuSave® CBD Nasal Spray is set to revolutionize how individuals approach nasal health.

Longboard Pharmaceuticals Announces Positive Topline Data from the PACIFIC Study, a Phase 1b/2a Clinical Trial, for Bexicaserin (LP352) in Participants with Developmental and Epileptic Encephalopathies (DEEs)

Retrieved on: 
Tuesday, January 2, 2024
Biotechnology, Neurology, Health, Pharmaceutical, Clinical Trials, Diarrhea, DSM-IV codes, Cannabidiol, Lethargy, Partnership, Constipation, Clobazam, Aes, Lamotrigine, Caregiver, Principal, Research, LGS, TID, DEE, ASMS, Medication, Data, Physician, Somnolence, MD, Doctor of Philosophy, DS, SAE, Seizure, Combination, Pharmacokinetics, Appetite, Participation, Patient, Diagnosis, Safety, Levetiracetam, MSCE, Pharmaceutical industry

Of the 52 participants enrolled in the study, 43 participants were randomized to bexicaserin (DS=4, LGS=24, DEE Other=15) and 9 to placebo (DS=0, LGS=5, DEE Other=4).

Key Points: 
  • Of the 52 participants enrolled in the study, 43 participants were randomized to bexicaserin (DS=4, LGS=24, DEE Other=15) and 9 to placebo (DS=0, LGS=5, DEE Other=4).
  • The median number of countable motor seizures per 28-day period at baseline was 38.8 in the bexicaserin group compared to 20.8 in the placebo group.
  • Most participants (85.7%) in the bexicaserin treated group (n=35) that started the maintenance period tolerated the highest dose (12 mg).
  • 100% of the participants who completed the PACIFIC Study elected to enroll in the ongoing 52-week open-label extension study.

Cardiol Therapeutics Announces Study Results Presented at the 2023 Annual Meeting of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases

Retrieved on: 
Thursday, November 16, 2023
Pericarditis, Cardiology, Cannabidiol, University, American Heart Association, Research, CRDL, Working Group, Health, Therapy, Cardiac muscle, MMT, Pericardium, Agent handling, Knowledge, Poster, Fibrosis, TSX, Diagnosis, Facial muscles, Heart failure, Wound healing, Pharmaceutical industry

An abstract summarizing these results was submitted by the Company's international research collaborators from the University of Virginia and Houston Methodist DeBakey Heart & Vascular Center to the 2023 Annual Meeting of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases ("MPD2023") held on November 15 and 16, 2023 in Belgrade, Serbia.

Key Points: 
  • An abstract summarizing these results was submitted by the Company's international research collaborators from the University of Virginia and Houston Methodist DeBakey Heart & Vascular Center to the 2023 Annual Meeting of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases ("MPD2023") held on November 15 and 16, 2023 in Belgrade, Serbia.
  • The poster entitled "Cannabidiol Inhibits the Mesothelial to Mesenchymal Transition in Experimental Pericarditis" was presented for general viewing within the poster sessions of the MPD2023 Scientific Programme.
  • The 2023 Annual Meeting of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases brings together a collaborative group dedicated to advancing knowledge, research, and clinical practises related to myocardial and pericardial diseases.
  • The Working Group aims to develop and disseminate guidelines, recommendations, and advancements in the field, ultimately enhancing patient care and outcomes for individuals affected by myocardial and pericardial diseases within the European and global medical community.

Artelo Biosciences Presents New Preclinical Data on ART12.11 at the 4th Annual Med-Cannabis 2023 Conference in Germany

Retrieved on: 
Tuesday, December 5, 2023
Fed, Cancer, Pain, Cannabidiol, TMP, Research fellow, Pharmaceutical industry

During the talk, “A novel cannabidiol:tetramethylpyrazine cocrystal improves the bioavailability and efficacy of CBD,” presented by George Warren, PhD., Principal Scientist at Artelo Biosciences, new data on ART12.11 demonstrating improved CBD bioavailability in both the fed and fasted states compared to CBD alone was discussed.

Key Points: 
  • During the talk, “A novel cannabidiol:tetramethylpyrazine cocrystal improves the bioavailability and efficacy of CBD,” presented by George Warren, PhD., Principal Scientist at Artelo Biosciences, new data on ART12.11 demonstrating improved CBD bioavailability in both the fed and fasted states compared to CBD alone was discussed.
  • The presentation included results from additional preclinical studies that demonstrated greater anxiolytic, anti-depressive, and pro-social effects of ART12.11 compared to CBD alone.
  • “ART12.11’s improved physiochemical properties continues to differentiate it from CBD alone,” commented Professor Saoirse O’Sullivan, Vice President of Translational Science at Artelo Biosciences.
  • “The therapeutic utility of CBD is hampered by its physical properties, including high lipophilicity, poor solubility and stability, as well as poor oral bioavailability.